DPP4 Inhibitor and Coronary Atherosclerosis in Patients Receiving Insulin Therapy
Effect of DPP4 Inhibitors on Coronary Atherosclerosis in Patients With Diabetes Mellitus on Insulin Therapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Bucheon, Korea, Republic of, KS013
- Bucheon St. Mary's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diabetes mellitus
- Receiving chronic insulin therapy (prescription of insulin pen)
- Who underwent more than 2 times of coronary CT scan
Exclusion Criteria:
- Age <18
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
DPP4-inhibitor
Patients who were prescribed DPP4-inhibitor during the period between two coronary CT scan.
|
Prescription of DPP4-inhibitor during the period between the two coronary CT scan
|
|
No DPP4-inhibitor
Patients who were not prescribed DPP4-inhibitor during the period between two coronary CT scan.
|
No prescription of DPP4-inhibitor during the period between the two coronary CT scan
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prevalence of obstructive coronary disease
Time Frame: one year
|
Change in the prevalence of obstructive coronary disease, defined as >50 percent stenosis in coronary CT scan
|
one year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in coronary calcium score
Time Frame: one year
|
Change in coronary calcium score, measured by two coronary CT scan per one year. Agatston score has minumum value of 0 and no maximum vavlue. Higher agatston score indicated severe calcification and worse outcome |
one year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Sang-Hyun Ihm, MD,PhD, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Glucose Metabolism Disorders
- Metabolic Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Endocrine System Diseases
- Coronary Disease
- Coronary Artery Disease
- Myocardial Ischemia
- Diabetes Mellitus
- Atherosclerosis
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protease Inhibitors
- Dipeptidyl-Peptidase IV Inhibitors
Other Study ID Numbers
Other Study ID Numbers
- XC21WIDI0044
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
NCT05168657CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1
-
NCT03811470RecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes Mellitus
-
NCT02722499CompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type II
-
NCT03332849UnknownType2 Diabetes Mellitus | Type1 Diabetes Mellitus
-
NCT00563004CompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes Mellitus
-
NCT04129424UnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative Period
-
NCT07228117RecruitingType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus
-
NCT07011147RecruitingDiabetes Mellitus | Diabetes | Type 2 Diabetes | Diabetes Mellitus Type 2 | Diabetes Mellitus, Type I | Diabetes Mellitus Type II | Diabetes Mellitus, Insulin-Dependent | Diabetes, Autoimmune | Type 1 Diabetes (T1D) | Diabetes Type 2 on Insulin
-
NCT03211858CompletedType 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
-
NCT02128854CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin Dependent
Clinical Trials on DPP4-inhibitor
-
NCT05359341Completed
-
NCT03046576CompletedCoronary Angiography | Dipeptidyl Peptidase 4
-
NCT06263673CompletedParkinson Disease | Lewy Body Dementia
-
NCT02182895Completed
-
NCT07374328Recruiting
-
NCT01176708Unknown
-
NCT07332156CompletedType 2 Diabetes | Lung Cancer (Diagnosis) | COPD (Chronic Obstructive Pulmonary Disease)
-
NCT06145360CompletedGlucose Metabolism Disorders | Diabetes Mellitus, Type 2 | Hypoglycemic Agents | Empagliflozin
-
NCT06075810RecruitingBreast Cancer | Breast Neoplasm | Breast Cancer Stage IV